|
Gender(male)
|
79 (82.3%)
|
108 (86.4%)
|
0.515
|
|
Age (>= 65 years)
|
15 (15.6%)
|
24 (19.2%)
|
0.608
|
|
Hepatitis
|
|
NBNC, n (%)
|
12 (12.5%)
|
18 (14.4%)
|
0.668
|
|
HBV, n (%)
|
82 (85.4%)
|
106 (84.8%)
|
|
HCV, n (%)
|
2 (2.1%)
|
1 (0.8%)
|
|
NAFLD, n (%)
|
5 (5.2%)
|
6 (4.8%)
|
1
|
|
Cirrhosis (yes)
|
65 (67.7%)
|
84 (67.2%)
|
1
|
|
Resection type (major resection)
|
70 (72.9%)
|
73 (58.4%)
|
0.036
|
|
Lymph node dissection (yes)
|
24 (25.0%)
|
16 (12.8%)
|
0.031
|
|
Tumor number (multiple)
|
30 (31.3%)
|
29 (23.2%)
|
0.235
|
|
Tumor size (>= 5 cm)
|
66 (68.8%)
|
55 (44.0%)
|
< 0.001
|
|
Tumor capsule (present)
|
52 (54.2%)
|
72 (57.6%)
|
0.709
|
|
Microvascular invasion (present)
|
77 (80.2%)
|
64 (51.2%)
|
< 0.001
|
|
Macrovascular invasion (present)
|
38 (39.6%)
|
16 (12.8%)
|
< 0.001
|
|
Satellite nodules (present)
|
48 (50.0%)
|
28 (22.4%)
|
< 0.001
|
|
Edmondson-Steiner classification (III/IV)
|
21 (21.9%)
|
26 (20.8%)
|
0.978
|
|
RBC(>= 4 × 10^12/L)
|
10 (10.4%)
|
13 (10.4%)
|
1
|
|
Hb(< 120*g/L)
|
7 (7.3%)
|
9 (7.2%)
|
1
|
|
PLT(< 300 × 10^9/L)
|
86 (89.6%)
|
117 (93.6%)
|
0.404
|
|
Neutrophil count(>= 5 × 10^9/L)
|
63 (65.6%)
|
97 (77.6%)
|
0.068
|
|
Lymphocyte count(>= 1.5 × 10^9/L)
|
23 (24.0%)
|
32 (25.6%)
|
0.902
|
|
NLR(> = 1.6)
|
18 (18.8%)
|
30 (24.0%)
|
0.439
|
|
AST(>= 40 U/L)
|
49 (51.0%)
|
56 (44.8%)
|
0.432
|
|
PT(>= 13 s)
|
35 (36.5%)
|
40 (32.0%)
|
0.582
|
|
TB(>= 17.1 umol/L)
|
22 (22.9%)
|
34 (27.2%)
|
0.569
|
|
ALB(< 40 g/L)
|
33 (34.4%)
|
48 (38.4%)
|
0.635
|
|
GGT(>= 75 U/L)
|
54 (56.3%)
|
47 (37.6%)
|
0.009
|
|
ALP(>= 78 U/L)
|
77 (80.2%)
|
72 (57.6%)
|
< 0.001
|
|
AFP(>= 20 ng/mL)
|
72 (75.0%)
|
72 (57.6%)
|
0.011
|
|
CEA(>= 5 ng/mL)
|
16 (16.7%)
|
18 (14.4%)
|
0.783
|
|
CA19-9(>= 25 U/mL)
|
63 (65.6%)
|
49 (39.2%)
|
< 0.001
|
|
DCP(>= 200 mAU/mL)
|
41 (42.7%)
|
32 (25.6%)
|
0.011
|
|
Intraoperative blood loss(>= 200 mL)
|
60 (62.5%)
|
63 (50.4%)
|
0.097
|
|
Intraoperative blood transfusion (yes)
|
28 (29.2%)
|
42 (33.6%)
|
0.578
|
